Cover Image
Market Research Report
Product code 
1037188

Aptamers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Published: | IMARC Services Private Limited | 141 Pages | Delivery time: 2-3 business days

Price

Back to Top
Aptamers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
Published: November 10, 2021
IMARC Services Private Limited
Content info: 141 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

The global aptamers market reached a value of US$ 4.3 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 20% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Aptamers are versatile oligonucleotides that bind to a specific target, including proteins, peptides, carbohydrates, small molecules, toxins, and live cells. They are modifiable, nonimmunogenic, highly sensitive, less toxic, easy to prepare and have low molecular weight and no variation with different preparations as compared to antibodies. As a result, they are widely being used in therapeutic and biotechnological applications. Besides this, they are also utilized as research agents, diagnostics, biosensors, and tools for biomarker or drug discovery worldwide.

Global Aptamers Market Trends:

The growing prevalence of life-threatening diseases, such as cancer, neurodegenerative, cardiovascular, and acquired immunodeficiency syndrome (AIDS), represents one of the key factors influencing the demand for new and effective detection assays based on aptamer therapy. Moreover, the advent of the chemical modification process to increase the nuclease resistance and enhance the therapeutic properties of aptamers is bolstering the market growth. The aptamers market growth can also be accredited to the rising number of research and development (R&D) activities undertaken for improving diagnostic devices and drugs and their carriers. Apart from this, as aptamers are chemically synthesized, which eliminates batch-to-batch variation and requires less time for development, their application is extensively increasing across the globe. Furthermore, private organizations are collaborating with academic institutes and research laboratories to introduce next-generation products and expand their existing market presence. This is anticipated to fuel the usage of aptamers in a wide range of medical therapies, as well as in the food and beverage (F&B) industry.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global aptamers market, along with forecasts at the global, regional and country-level from 2021-2026. Our report has categorized the market based on type and application.

Breakup by Type:

  • Nucleic Acid
  • Peptide

Breakup by Application:

  • Diagnostics
  • Therapeutics
  • Research and Developments
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Aptagen LLC, Aptamer Group, Aptamer Sciences Inc., Aptus Biotech S.L., Base Pair Biotechnologies Inc., IBA GmbH, Kaneka Eurogentec S.A. (Kaneka Corporation), NeoVentures Biotechnology Inc., NOXXON Pharma, SomaLogic Inc., TriLink BioTechnologies LLC and Vivonics Inc.

Key Questions Answered in This Report:

  • How has the global aptamers market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global aptamers market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global aptamers market and who are the key players?
  • What is the degree of competition in the industry?
Product Code: SR1020G209_Report

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Aptamers Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Nucleic Acid
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Peptide
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Diagnostics
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Therapeutics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Research and Developments
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Aptagen LLC
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
    • 13.3.2 Aptamer Group
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Aptamer Sciences Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Aptus Biotech S.L.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
    • 13.3.5 Base Pair Biotechnologies Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 IBA GmbH
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
    • 13.3.7 Kaneka Eurogentec S.A. (Kaneka Corporation)
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
    • 13.3.8 NeoVentures Biotechnology Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
    • 13.3.9 NOXXON Pharma
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
    • 13.3.10 SomaLogic Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
    • 13.3.11 TriLink BioTechnologies LLC
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
    • 13.3.12 Vivonics Inc.
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio